An Open-Label Exploratory Clinical Trial Evaluating the Effects of GLS (Coptidis Rhizoma-Evodiae Fructus 2 : 1) on Fibroblast Growth Factor 21 in Patients with Nonalcoholic Fatty Liver Disease
Table 4
Correlation between serum FGF 21 and other parameters changes.
Variables
GLS (n = 59)
PPC (n = 60)
Pearson correlation
Pearson/Spearman correlation
FGF 21 change (variable)
FGF 21 change (variable)
r
r
Weight change
0.000
0.999
0.143
0.275
Body mass index change
−0.028
0.833
0.151
0.249
Waist circumference change
0.343
0.008
0.065
0.621
Waist-to-hip ratio change
0.342
0.008
0.065
0.620
Controlled attenuation parameters change
0.315
0.015
0.158
0.229
Alanine transaminase change
−0.015
0.913
−0.072
0.585
Aspartate transaminase change
−0.077
0.564
−0.099
0.454
Gamma-glutamyl transferase change
0.374
0.004
−0.072
0.587
Triglyceride change
0.151
0.254
0.137
0.294
Total cholesterol change
0.016
0.906
0.055
0.676
High-density lipoprotein cholesterol change
−0.144
0.278
0.194
0.138
Low-density lipoprotein cholesterol change
0.232
0.077
−0.083
0.530
Glucose change
0.029
0.830
−0.081
0.539
aThe -values compare the significance levels of linear correlation between serum FGF 21 and other parameters changes.
